Terms: = Endocrine gland cancer AND USP8, FLJ34456, 9101, ENSG00000138592, KIAA0055, P40818, MGC129718, UBPY, HumORF8 AND Treatment
15 results:
1. Clinical Spectrum of usp8 Pathogenic Variants in Cushing's Disease.
Rebollar-Vega RG; Zuarth-Vázquez JM; Hernández-Ramírez LC
Arch Med Res; 2023 Dec; 54(8):102899. PubMed ID: 37925320
[TBL] [Abstract] [Full Text] [Related]
2. The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.
Vuong HG; Dunn IF
Endocrine; 2023 Dec; 82(3):527-535. PubMed ID: 37462809
[TBL] [Abstract] [Full Text] [Related]
3. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract] [Full Text] [Related]
4. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells.
Colombo D; Gatti L; Sjöstrand L; Carenini N; Costantino M; Corna E; Arrighetti N; Zuccolo M; De Cesare M; Linder S; D'Arcy P; Perego P
Biochem Pharmacol; 2022 Mar; 197():114900. PubMed ID: 34995485
[TBL] [Abstract] [Full Text] [Related]
5. usp8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
[TBL] [Abstract] [Full Text] [Related]
6. The clinical aspects of pituitary tumour genetics.
Dénes J; Korbonits M
Endocrine; 2021 Mar; 71(3):663-674. PubMed ID: 33543431
[TBL] [Abstract] [Full Text] [Related]
7. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.
Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
[TBL] [Abstract] [Full Text] [Related]
8. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract] [Full Text] [Related]
9. usp8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
Uzilov AV; Taik P; Cheesman KC; Javanmard P; Ying K; Roehnelt A; Wang H; Fink MY; Lau CY; Moe AS; Villar J; Bederson JB; Stewart AF; Donovan MJ; Mahajan M; Sebra R; Post KD; Chen R; Geer EB
J Clin Endocrinol Metab; 2021 Mar; 106(3):826-842. PubMed ID: 33221858
[TBL] [Abstract] [Full Text] [Related]
10. Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Vandeva S; Daly AF; Petrossians P; Zacharieva S; Beckers A
Eur J Endocrinol; 2019 Dec; 181(6):R235-R254. PubMed ID: 31658440
[TBL] [Abstract] [Full Text] [Related]
11. Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing.
Sesta A; Cassarino MF; Terreni M; Ambrogio AG; Libera L; Bardelli D; Lasio G; Losa M; Pecori Giraldi F
Neuroendocrinology; 2020; 110(1-2):119-129. PubMed ID: 31280266
[TBL] [Abstract] [Full Text] [Related]
12. [Pituitary adenomas].
Honegger J; Nasi-Kordhishti I; Giese S
Nervenarzt; 2019 Jun; 90(6):568-577. PubMed ID: 30997549
[TBL] [Abstract] [Full Text] [Related]
13. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Ben-Shlomo A; Cooper O
Curr Opin Endocrinol Diabetes Obes; 2017 Aug; 24(4):301-305. PubMed ID: 28520590
[TBL] [Abstract] [Full Text] [Related]
14. Cushing's disease: towards precision medicine.
Kaiser UB
Cell Res; 2015 Jun; 25(6):649-50. PubMed ID: 25930709
[TBL] [Abstract] [Full Text] [Related]
15. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
[TBL] [Abstract] [Full Text] [Related]
